Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition containing ginseng polysacchride and astragalus polysaccharide, its preparation and application

A technology of astragalus polysaccharides and ginseng polysaccharides, which can be used in drug combinations, medical preparations containing active ingredients, drug delivery, etc., and can solve problems such as unretrieved traditional Chinese medicine injection preparations

Inactive Publication Date: 2005-07-06
张平
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Checking the patent literature, no Chinese medicine injection preparations prepared from ginseng and astragalus were found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Inhibitory Effect on Liver Tumor in Rats with Qi Deficiency

[0035] Experimental animals: Rats, 150g~180g, male or female. (The qi deficiency model was created by the Department of Pharmacology of Traditional Chinese Medicine of Shenyang Pharmaceutical University based on the literature)

[0036] Experimental drug: each group of preparations of the present invention (prepared from effective parts of polysaccharides, provided by the laboratory of Guangdong Tianzhijiao Drug Development Co., Ltd.)

[0037] Astragalus polysaccharide powder injection (provided by Shanxi Academy of Traditional Chinese Medicine)

[0038] normal saline

[0039] Experimental method: take rats for intrahepatic inoculation of W256, 7 days after inoculation, anesthetize by intraperitoneal injection of pentobarbital sodium at a dose of 35 mg / kg, fix, expose the liver by laparotomy, and measure the maximum diameter of the tumor surface on the liver (a) and Minimum diameter (b), according to (a*b ...

Embodiment 2

[0060] Physical, chemical and biological factors can all induce cancer, but 80%-90% of the causes of human cancer are believed to be caused by environmental chemicals.

[0061] Inhibition of diethylnitrosamine (DENA)-induced liver cancer in rats

[0062] Experimental animals: 30 rats, about 120g, male or female, (Qi deficiency model was created by the Pharmacology Department of Traditional Chinese Medicine of Shenyang Pharmaceutical University according to the literature)

[0063] Experimental drug: each group of preparations of the present invention (prepared from effective parts of polysaccharides, provided by the laboratory of Guangdong Tianzhijiao Drug Development Co., Ltd.)

[0064] Astragalus polysaccharide powder injection (provided by Shanxi Academy of Traditional Chinese Medicine)

[0065] normal saline

[0066] Experimental method: Rats were fed with drinking water containing diethylnitrosamine (DENA), and primary liver cancer was obtained in 36 weeks. The experime...

Embodiment 3

[0087] Mice S 180 tumor growth inhibitory effect

[0088] Experimental animals: healthy mice, weighing 16-20g, half male and half male. (The qi deficiency model was created by the Department of Pharmacology of Traditional Chinese Medicine of Shenyang Pharmaceutical University based on the literature)

[0089] Tumor strain: mouse S 180

[0090] Experimental drug: each group of preparations of the present invention (prepared from effective parts of polysaccharides, provided by the laboratory of Guangdong Tianzhijiao Drug Development Co., Ltd.)

[0091] Astragalus polysaccharide powder injection (provided by Shanxi Academy of Traditional Chinese Medicine)

[0092] normal saline

[0093] Experimental method: Take the inoculated passage mouse S 180 , add saline to the homogenizer to make mouse S 180 Tumor homogenate was diluted with normal saline 1:3, and then 0.2ml was injected into the left armpit subcutaneous of mice, and weighed in 24 hours. The mice were administered on...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition containing ginseng polysacchride and astragalus polysaccharide, its preparation and use, pharmacological experiment has shown that, the pharmaceutical composition preparation of the polysaccharides effective parts provided by the invention has better pharmaceutical actions to vital energy deficiency type neoplastic diseases.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine pharmacy, and specifically relates to a pharmaceutical composition containing ginseng polysaccharide and astragalus polysaccharide and its preparation and application. Background technique [0002] In the prescription of traditional Chinese medicine, the combination of drugs with similar performance and efficacy can enhance the curative effect. This is an important content of "combination" in the selection of prescriptions in the treatment of diseases in traditional Chinese medicine. [0003] The determination of traditional Chinese medicine compound is to determine the treatment method on the basis of analyzing the pathogenesis, and form a prescription that meets the needs of the disease under the guidance of the treatment law. The method of treatment is based on the selection of appropriate drugs and the appropriate dosage of drugs, and is combined under the guidance of the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/08A61K9/14A61K31/715A61P35/00
Inventor 张平
Owner 张平
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com